Clinical trials: Corona Virus Disease
Covid19
Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of patients in Clinical Trial…
- Trial name
- NCT04891172
- Testing
- Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)
- Where
- Pakistan
- Volunteers
- 310 people
- Sponsor
- Dow University of Health Sciences
SARS-CoV Infection, COVID-19
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
There is emerging evidence that patients with SARS-CoV-2 are affected by increased coagulopathy, including in the most advanced forms, a fully blown disseminated intravascular coagulation, leading to multi organ failure (MOF).
- Trial name
- CONVINCE (NCT04516941)
- Testing
- Edoxaban Tablets, Colchicine Tablets
- Where
- 5 sites in Belgium, Italy and 1 more
- Volunteers
- 60 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Infectious Metabolic Encephalopathy, Ischemic Stroke
Procedural Motor Memory in Long COVID-19
Background: Most people who get COVID-19 seem to recover with no long-term effects. However, some people who recover from acute COVID-19 infections report lingering symptoms. This is called long COVID.
- Conditions
- Infectious Metabolic Encephalopathy, Ischemic Stroke, Seizure, Viral Encephalitis, Small and Large Vessel
- Trial name
- NCT05746624
- Testing
- keypresses
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
COVID-19, Cardiovascular Diseases
The COVID-RASi Trial (COVID-19)
The COVID-RASi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in COVID-19 patients.
- Trial name
- NCT04591210
- Testing
- Angiotensin converting enzyme inhibitor, Angiotensin II Receptor Blockers
- Where
- 31 sites in Brazil, Canada and 1 more
- Volunteers
- 372 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Covid19, Hypertension
Inspiratory Muscle Trainer and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Persistent Symptoms
Inspiratory muscle training considered as safe and valid method to improve respiratory muscle strength and functional capacity among uncountable conditions which could improve post COVID-19 persistent symptoms including but not…
- Conditions
- Covid19, Hypertension, Corona Persistent Symptoms
- Trial name
- NCT04919031
- Testing
- Inspiratory muscle trainer, diaphragmatic release
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
COVID-19, Acute Respiratory Distress Syndrome
Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19
The purpose of this study is to demonstrate the safety of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UCMSCs) administered intravenously in patients with acute pulmonary inflammation due to COVID-19 with moderately…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Corona Virus Infection
- Trial name
- COVID-19 (NCT04490486)
- Testing
- UCMSCs
- Sponsor
- Joshua M Hare
Covid19
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
This multi-center, double-blind, placebo-controlled, randomized Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in patients hospitalized with confirmed COVID-19.
- Trial name
- NCT04494646
- Testing
- Bardoxolone Methyl
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- NYU Langone Health
Mental Health Wellness 1
#Stayhealthy - Monitoring and Maintenance of Mental Health Under Conditions of Social Isolation During the Corona Crisis
The COVID-19 pandemic has led to a global health crisis with, so far, over 21 million registered cases and more than 700.000 deaths worldwide.
- Trial name
- stayhealthy (NCT04871386)
- Testing
- Acceptance and commitment therapy (ACT) exercises, Positive psychology (PP) exercises
- Where
- Germany
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Corona Virus Infection
Serology COVID-19 From the Cornwall Hospital Union
Coronavirus (COVID-19) is a pandemic-like disease caused by a new coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) isolated in China in 2019.
- Trial name
- ROCOCO (NCT04363593)
- Testing
- Serological test, Serum test
- Where
- France
- Volunteers
- 2,587 people
- Sponsor
- Centre Hospitalier de Cornouaille
Treatment of Covid-19 Virus Infection
Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients
While novel drug discovery and vaccine studies are time taking process, re-purposing old drugs against the COVID-2019 epidemic can help identify treatments, with known pre-clinical, pharmacokinetic, pharmacodynamic, and toxicity…
- Trial name
- NCT04494204
- Testing
- Immunofree tablets and Reginmune capsule
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- PUNEET MITTAL
Covid19, COVID-19 Pneumonia
imPulse™ Una Infrasound-to-ultrasound E-stethoscope
This study generates robust, uniform clinical data across emerging COVID-19 strains to train ML/AI algorithms of the Sponsor's imPulse™ Una infrasound-to-ultrasound e-stethoscope for digital diagnostic feature synthesis of…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT04941209
- Testing
- imPulse™ Una infrasound-to-ultrasound e-stethoscope, (PPA >95%) FDA EUA RT-PCR, HR-CT-scan
- Where
- 3 sites in Democratic Republic of the Congo, India and 1 more
- Volunteers
- 702 people
- Sponsor
- Level 42 AI, Inc.
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
COVID-19 Respiratory Infection
An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia
This is a multicenter, ambispective observational cohort study. The patients with corona virus disease 2019 (COVID-19) will be included in the study.
- Trial name
- NCT05621993
- Testing
- Azvudine
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Qianfoshan Hospital
Corona Virus Infection
Demographics and Outcomes of COVID 19 in Pregnancy at a Community Based Hospital
Demographics of pregnant COVID persons under investigation and those who were positive from March-May 2020. Looking at demographics including age, socio-economic status and pregnancy outcomes in these groups.
- Trial name
- NCT04385914
- Testing
- COVID positive via testing
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Atlantic Health System
Corona Virus Infection, Hypoxic Respiratory Failure
Timed Awake Prone and Repositioning for Patients With Covid-19-induced Hypoxic Respiratory Failure.
Awake prone positioning has been reported to improve oxygenation for patients with COVID-19. Awake timed and repositioning is a novel method to improve patients' compliance and prolong the prone time.
- Trial name
- NCT05689216
- Testing
- Awake timed prone and repositioning
- Where
- 3 sites in China
- Volunteers
- 286 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
COVID-19
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity…
- Trial name
- DAP-CORONA (NCT04935476)
- Testing
- Dapsone 85 mg PO BID
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,000 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID, Sars-CoV2
Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019…
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection, Myositis
- Trial name
- NCT04367350
- Testing
- laboratory biomarkers, muscle ultrasound
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Tuebingen
Covid19, Diarrhea
COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience
The present study conducted to correlate symptoms not only constitutional and respiratory, but GIT as a principle presentation, with laboratory markers and COVID-19 severe acute respiratory syndrome (SARS-COV2) disease outcomes…
- Trial name
- NCT04554979
- Testing
- Hydroxychloroquine Pill
- Where
- Egypt
- Volunteers
- 199 people
- Sponsor
- Cairo University
Corona Virus Disease 19 (COVID-19), COVID
Rehabilitation for People With COVID-19 in ICU
COVID-19 DISEASE Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, severe acute respiratory syndrome from COVID-19, that was first recognized in Wuhan, China, in December…
- Conditions
- Corona Virus Disease 19 (COVID-19), COVID, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Critical Illness
- Trial name
- COVID_REHAB (NCT04381338)
- Testing
- Pulmonary and Motor Rehabilitation
- Where
- 2 sites in Italy
- Volunteers
- 96 people
- Sponsor
- University of Padova